Metastases reduction

Unlike the situation with the integrins discussed earlier, it is loss of cadherin E that promotes metastasis. The evidence linking loss or decreased expression of cadherin E with cancer spread is as follows (M2). Firstly, a negative correlation exists between the expression of cadherin E and invasion for many different cancer cell lines. Secondly, in cell lines lacking cadherin E, invasion could be prevented by transfection with cDNA for this cadherin. Thirdly, reduction in cadherin E mRNA levels by antisense sequences induced the invasive phenotype in E-cadherin positive cells. Fourthly, antibodies inactivating cadherin E induced the invasive phenotype. These combined experiments are strong evidence that loss of cadherin E is associated with development of invasive phenotype and furthermore suggests that this adhesion molecule may be a suppressor of metastasis. 

VIII. Cysmethynil Inhibition of Icmt Results in Reduction of Rho-Medioted Cell Migration/ Suggesting a Potential Role in Cancer Metastasis... 

Rotational stress caused a significant reduction in the number of CD3+ and CD4+ T-lymphocyte subsets in summer, whereas in winter the number of CD3+ subset was significantly increased the CD4+/CD8+ ratio and the number of NK 1.1 antigen positive cells were not significantly modified by rotational stress in both periods considered. The increase in metastasis formation by rotational stress thus appears to negatively correlate with the number of splenic CD3+ and CD4+ T-lymphocyte subsets (Perissin et al., 1998). 

As shown in Fig. (27) , 4-hydroxyderricin (25 or 50 mg/kg, twice daily) inhibited metastasis to the lung in tumor-removed mice and the increase of lung weight that occurred in tumor-removed mice. In this study, we found that the number of lymphocytes, CD4" T, CDS T and NK cells in the spleen of LLC-removed mice were reduced compared to those of normal mice. 4-Hydroxyderricin (50 mg/kg x 2/day) inhibited the reduction of lymphocyte, CD4 and CDS" T cells and NK cell number in tumor-removed mice. On the other hand, the numbers of lymphocytes, CD4 T, CD8 T and NK cells were further reduced by the intraperitoneal administered doxorubicin compared to LLC-removed mice Table (18) . 

The phase I experience with SCH66336 involved 20 patients using a twice a day schedule over 7 days every 21 days. A recommended phase II dose of 350 mg was determined, with DLT consisting of severe fatigue. Eight patients had stable disease, and treatment for up to 10 cycles was possible in a few patients. Antitumor activity was reported in one patient with advanced NSCLC who had a greater than 50% reduction in an adrenal metastasis and received treatment for 14 months (174). 

---